Literature DB >> 11209986

Thrombomodulin: a linker of coagulation and fibrinolysis and predictor of risk of arterial thrombosis.

K K Wu1, N Matijevic-Aleksic.   

Abstract

Thrombomodulin (TM) binds thrombin, changes thrombin conformation and allows thrombin to activate protein C and thrombin-activatable fibrinolysis inhibitor (TAFI). Activated protein C and TAFI inhibit coagulation and fibrinolysis, respectively. TM is, thus, a linker of endogenous control of coagulation and fibrinolysis. Plasma soluble TM, cleaved products of cellular TM, also have anticoagulant and antifibrinolytic properties. TM plays an important role in thromboresistance. Prospective studies show that a high plasma TM level is associated with a low risk of developing coronary heart disease. The plasma TM level may reflect the level of endothelial TM expression. TM expression levels are influenced by multiple gene polymorphisms. Several of the polymorphisms are probably associated with coronary heart disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11209986

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  6 in total

1.  Does the oxidation of methionine in thrombomodulin contribute to the hypercoaguable state of smokers and diabetics?

Authors:  Wesley E Stites; Jeffrey W Froude
Journal:  Med Hypotheses       Date:  2006-10-24       Impact factor: 1.538

Review 2.  Hypercoagulable states and strokes.

Authors:  Nena Matijevic; Kenneth K Wu
Journal:  Curr Atheroscler Rep       Date:  2006-07       Impact factor: 5.113

3.  Does administration of eicosapentaenoic acid increase soluble thrombomodulin level in statin-treated patients with stable coronary artery disease?

Authors:  Shigemasa Tani; Rei Matsuo; Atsushi Hirayama
Journal:  Heart Vessels       Date:  2018-08-24       Impact factor: 2.037

4.  Assessment of coronary heart disease risk by combined analysis of coagulation factors.

Authors:  Nena Aleksic; Yao-Wei W Wang; Chul Ahn; Harinder S Juneja; Aaron R Folsom; Kenneth K Wu
Journal:  Atherosclerosis       Date:  2008-03-14       Impact factor: 5.162

5.  Changes in Biomarkers of Coagulation, Fibrinolytic, and Endothelial Functions for Evaluating the Predisposition to Venous Thromboembolism in Patients With Hereditary Thrombophilia.

Authors:  Lei Li; Lixia Gao; Xi Wu; Wenman Wu; Qiulan Ding; Xuefeng Wang
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

Review 6.  Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment.

Authors:  Hugo Ten Cate; Tomasz J Guzik; John Eikelboom; Henri M H Spronk
Journal:  Cardiovasc Res       Date:  2021-07-27       Impact factor: 10.787

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.